Biopharmaceutical company ANI Pharmaceuticals Inc (Nasdaq:ANIP) said on Tuesday that it has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding LLC (SWK) on worldwide net revenues from ILUVIEN and YUTIQ.
The one-time payment of USD17.25m eliminates the royalty obligation, effective from 1 January 2025.
The buyout was funded using ANI's cash on hand. This transaction is part of ANI's strategy to strengthen its Retina portfolio and maximise the long-term value of ILUVIEN and YUTIQ.
Nikhil Lalwani, president and CEO of ANI, emphasized that this move enhances the company's financial flexibility and supports its goal of accelerating growth and improving patient outcomes.
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo